Amgen and Takeda's late-stage trial of motesanib failed to improve the overall survival rate of patients with late stage lung cancer (specifically advanced non-squamous non-small cell). Side effects in the study were also reported to be most severe with patients receiving the drug.
Takeda paid $100 M upfront to partner with Amgen on the drug only 2 years ago. It was part of a $1 billion dollar deal with Amgen to allow Takeda to get more deeply involved in the biologics sector, and to expand its cancer portfolio in the US. See Fierce Biotech.
"We are disappointed with the results from this trial, but look forward to further analysis [ed. note, always kiss of death when you read this] of the data which may ultimately help inform future research in this area," said Roger Perlmutter, Amgen executive VP of R&D. See Reuters.
Posted by Bruce Lehr March 30th 2011.